Project title: BIOLOGICAL IMPLANT FOR BONE AND CARTILAGE REGENERATION

Company name : REGENTIS BIOMATERIALS LTD.

LTD.

TECHNOLOGICAL FIELD
Biotechnology, Tissue
Regeneration

KEY WORDS
Tissue Regeneration, Cartilage, Bone,
Spinal Fusion, Orthobiologics

PROJECT SUMMARY
Regentis Biomaterials, Ltd. is a medical material development
company that is focused on commercializing its patent-applied
Gelrin Platform Technology for bone, spine and cartilage repair.

The company has developed the state-of-the-art tissue
regeneration substrate called Gelrin with the participation of
leading biomaterial scientists and orthopedic surgeons. The
Gelrin technology is based on a biosynthetic hybrid hydrogel
comprised of a biological backbone and synthetic cross-links.
The biological domains in the material endow Gelrin with
excellent healing properties, while the synthetic cross-links
provide the material superior physical characteristics. The
biodegradation of Gelrin is fully controllable and enables
precise regulation over the ingrowth kinetics and healing
properties. The ability to form Gelrin in-situ at the site of
the defect provides the possibility of using it with minimally
invasive surgical procedures. While other materials degrade
rapidly or leach out of the injury site prematurely, Gelrin
remains anchored during the entire healing process. This unique
combination of properties makes Gelrin highly distinctive in the
orthopedic market.

The main product in development is GelrinCartilage - a
chondrogenically enriched ingrowth matrix for cartilage
regeneration. Two additional pipeline products are planned,
including GelrinBone - a unique ingrowth matrix for bone
regeneration in bone injuries; and GelrinSpine - an enhanced
ingrowth matrix for non-injurious bone formation and spinal
fusion.

MARKETS
The orthopedic market segments are clearly defined and are
subject to an average annual compound growth rate of 13%. Total
expected market value by 2007 is US $24B. The bone regeneration
market value is expected to reach US $2.2B in annual sales by
2008 with an annual growth rate of 19%. The cartilage
regeneration market value is expected to reach US $1.6B in annual
sales by 2008 with an annual growth rate of 11%.

ENTREPRENEURS
Mr. Yehiel Tal - CEO and Co-Founder,
M.Sc. in Mechanical Engineering, 17 years of management
experience in Israeli and American high-tech and biotech
industries.
Dr. Dror Seliktar - CSO and Co-Founder,
Ph.D. in Biomedical Engineering, 12 years of biomaterials and
tissue engineering research experience in American, European, and
Israeli Academic Institutions.

PROJECT STATUS
Recently, the company has secured a series B investment round of
$7.5M to complete human clinical trials for GelrinCartilage and
GelrinBone in Europe.
The company plans to have its first orthopedic product line based
on the Gelrin technology in the development and implementation
stage within the next three years.

COOPERATION REQUIRED
First round investment and strategic partners.
---------------------------------------------------------------
TEL: 972-4-8546617; FAX: 972-4-8546644; E-MAIL:
yehiel@regentis.co.il, WEB: www.regentis.co.il

Request for more information, about this project.

Note - you have to be registered in this server to request information. If you haven't done so yet, please:
Register in this server and your requests will be forwarded to the developer, who will contact you directly

List of projects that you already requested more information about